Can an injection boost energy? new study tests niagen plus for fatigue
NCT ID NCT07251608
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing the safety of Niagen Plus, an injectable form of vitamin B3, in 40 healthy adults who feel tired. Participants will receive injections under the skin or into muscle over 100 days. Researchers will monitor side effects and measure changes in NAD+ levels, fatigue, sleep, and quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Feb 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Generally healthy adults, aged 18+ * Demonstrated baseline fatigue as determined by a below average score from the FAS (threshold prespecified in SAP). * NAD+ or NAD+ precursor injection naïve (including intravenous, intramuscular, subcutaneous, or other injection route) (i.e., 8 weeks abstinent) * Non-anemic * Willingness to adhere to lifestyle considerations and study procedures. * Ability to read English, and provide written informed consent. * Willingness to self-administer the study material, via subcutaneous injection for 90 days (days 10-100 of the study), and complete finger prick blood collections. Exclusion Criteria: * One or more uncontrolled chronic illness including but not limited to diabetes, cardiovascular disease, liver, disease, kidney disease, or any form of cancer. An uncontrolled chronic illness, in this case, is defined as any changes to medication or other treatment modalities in the last 90 Days. * More than one chronic disease diagnosis under active treatment. * Any chronic disease, as determined by the primary investigator, that increases risk or confounds safety. * Any acute illness within 14 Days prior to Visit 1 (Day 1). * Cancer diagnosis within the last 5 years * Anemia (as defined by hemoglobin levels below 100 g/L, and other blood measures) * Current pregnancy or lactation; unwilling to use effective contraception if of childbearing potential. * Use of any NAD+ supplement, NAD+ precursor, or vitamin B3 product, orally, nasally, by patch, or injection within the last 60 Days. NAD+ precursors and related compounds include niacin (NA), nicotinamide (NAM), nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), NAD+, NADH, NAD+3, inositol hexanicotinate, apigenin; etc. The exception is the use of a daily oral multivitamin, that may contain vitamin B3 (niacin/nicotinamide). Such use will need to be documented. * Hypersensitivity or allergy to NR, niacin, other forms of vitamin B3/NAD+ precursors, bacteriostatic water * Significant aversion to needles or finger pricks. * Participation in another clinical intervention study, 90 Days (or 5 half-lives of the intervention, whichever is longer) prior to Visit 1 (Day 1). * Any other condition rendering the participant unsuitable per investigator. * Excessive daily use of alcohol, defined as 4 or more drinks on one occasion, or illicit drug use which would prevent adherence to the protocol as determined by the investigator.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Fatigue are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
BTT Medical Institute Aventura North
RECRUITINGMiami, Florida, 33180, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can exercising with your baby reshape postpartum recovery?
- Experimental brain drug TAK-935 put to the test in healthy volunteers
- Tracing a Low-THC cannabis extract through the human body
- Exercise as a potential remedy for IBD-related fatigue
- Can a new injection SGB-9768 pass its first safety test?
- Can a new PET tracer reveal the Body's hidden stress?